The use of prostate-specific membrane antigen (PSMA)-targeted PET imaging has revolutionized the primary staging, therapy monitoring and assessment of recurrent disease in men with prostate cancer, with a significant impact on management and clinical outcomes. This evidence concerns the gene FOLH1 and prostate cancer.